Top Injectable Manufacturer in Peru – Reliable Pharmaceutical Solutions
- Maulik Sudani
- Jul 21
- 9 min read
Last Updated: July 21, 2026
TL;DR: Peru is a market of roughly 35 million people that imports around two-thirds of the medicines it consumes, with domestic production estimated at about a third of the total and shrinking. Cancer is now the country's leading cause of death, anaemia affects 43.4% of children aged 6 to 35 months, and tuberculosis notifications reached 33,049 in 2024 — all of which sustain steady demand for sterile injectables across oncology, anti-infectives, parenteral iron and hospital essentials. Access runs through DIGEMID, the medicines directorate of the Ministry of Health, which grants a five-year Registro Sanitario on a CTD dossier filed by a Peruvian droguería. The decisive fact for any Indian manufacturer is that India does not appear on DIGEMID's list of “países de alta vigilancia sanitaria”, so a home-country GMP certificate is not accepted as a substitute: the plant needs a BPM certificate issued by DIGEMID itself following an on-site inspection in India. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Peruvian partners with CTD dossiers, apostilled documentation, Zone IVa and IVb stability packages and inspection-ready plant access.
Key Takeaways
Regulatory pathway, precisely: the marketing authorisation is the Registro Sanitario, granted by DIGEMID under Ley N° 29459 and DS N° 016-2011-SA, valid five years and renewable, on a CTD-structured dossier filed electronically. The holder must be a Peruvian pharmaceutical establishment — in practice a droguería with a Buenas Prácticas de Almacenamiento certificate and a Químico Farmacéutico as Director Técnico — so registration is always a joint project with a local partner.
The inspection reality, stated plainly: India is not among the twenty “países de alta vigilancia sanitaria” whose GMP certificates DIGEMID accepts, and India is not a PIC/S member, so there is no mutual-recognition shortcut. Between November 2025 and May 2026 DIGEMID assessed 70 plants across six countries; of the first 51 inspected, only 20 obtained BPM certification. A manufacturer that can host and pass that inspection is in a materially stronger position than one that cannot.
Documentation runs on apostille, not consularisation. Peru has been a party to the Hague Apostille Convention since 30 September 2010 and India is also a party, so the Certificate of Pharmaceutical Product and GMP certificate are apostilled and translated into Spanish rather than routed through consular legalisation — a real saving in time and cost that many exporters still fail to plan for.
Stability data must match the climate DIGEMID actually specifies. Peru is classified ICH Climatic Zone IVa, with long-term storage at 30°C/65% RH and accelerated at 40°C/75% RH. Zone IVb data at 30°C/75% RH exceeds that requirement and de-risks distribution into the humid Amazon regions, which is why Farbe Firma files the more demanding package.
Introduction: Why an Injectable Manufacturer in Peru Must Meet Global Standards
Peru's health system serves roughly 35 million people through several parallel networks that buy medicines in quite different ways. The Ministry of Health and the regional governments cover the majority of the population and procure centrally through CENARES, the national strategic-resources purchasing centre. EsSalud, the social health insurance system, runs its own hospital network and its own tenders; in 2025 alone it recorded 24,749,078 outpatient consultations and 428,505 surgeries across facilities including the Edgardo Rebagliati Martins and Guillermo Almenara Irigoyen hospitals. Alongside these sit the armed forces and police systems and a substantial private sector. For a sterile injectable supplier, the practical consequence is that a single national registration opens several distinct commercial doors, each with its own qualification and contracting rhythm.
The demand side is unambiguous. Cancer has become Peru's leading cause of death, with 40,830 deaths recorded in 2025 at a mortality rate of 119 per 100,000 — up roughly a quarter on the 2019 rate — and around 56% of cases still diagnosed at an advanced stage, which pushes treatment toward parenteral oncology regimens. Anaemia remains stubbornly high, affecting 43.4% of children aged 6 to 35 months according to ENDES 2025, sustaining demand for parenteral iron. Tuberculosis notifications reached 33,049 in 2024 against a WHO-estimated true burden considerably higher, with Lima Metropolitana carrying a morbidity rate of 142.4 per 100,000 against a national 96.9. Meanwhile domestic manufacturing has thinned: industry estimates put local production at around 34% of the market, with imports channelling roughly two-thirds. Peru needs reliable imported sterile injectables, and it needs them from manufacturers whose quality systems will survive scrutiny.
What Sets a World-Class Injectable Manufacturer in Peru Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line added. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma's operation in Gujarat, India is built around ISO Class 5 aseptic filling zones under classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing depending on the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. That architecture is what turns a certificate of analysis into a defensible claim, and it is precisely what an inspector arriving from Lima will be looking for.
The second differentiator is market-access support built around Peru's actual pathway, including the parts that are inconvenient. The Registro Sanitario is granted by DIGEMID under Ley N° 29459 and its implementing regulation DS N° 016-2011-SA, runs for five years, and is filed on a CTD-structured dossier through Peru's electronic single-window channels. The titular cannot be a manufacturer sitting in Gujarat: it must be a Peruvian pharmaceutical establishment, ordinarily a droguería holding a Buenas Prácticas de Almacenamiento certificate and employing a Químico Farmacéutico as Director Técnico, who signs the application and carries legal accountability for the portfolio. A useful supplier therefore does not simply ship product; it builds the dossier its Peruvian partner will file, supplies apostilled CPP and GMP documentation with certified Spanish translations, prepares Spanish artwork that matches the authorisation exactly — DIGEMID reports that mismatch between printed labelling and approved artwork is the single most common cause of regulatory observations — and then makes the plant available for inspection.
Quality Systems Behind Every Batch We Ship to Peru
Every Farbe Firma injectable batch destined for Peru is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits. Water content is determined by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis rather than left implicit.
Behind release testing sits the quality architecture that makes those results meaningful. Stability programmes run on three batches under real-time conditions per ICH Q1A, with photostability per ICH Q1B where the molecule warrants it; for Peru we hold long-term data at the Zone IVa condition of 30°C/65% RH and, as standard, the more demanding Zone IVb package at 30°C/75% RH, which covers humid Amazonian distribution and simplifies dossier reuse across other tropical markets. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, and batch records are retained so that any vial can be reconstructed from raw material to release years later. Dossiers are compiled in CTD or ACTD format as the destination requires, and the site is maintained in a state of continuous inspection readiness — which, given DIGEMID's current inspection programme, is not an abstract virtue.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Peru for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, vitamins and parenteral nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals. For a Peruvian droguería assembling a hospital portfolio, or a supplier qualifying for CENARES and EsSalud tenders, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single distributor's launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We support dossier preparation in CTD format for the Registro Sanitario, provide apostilled Certificates of Pharmaceutical Product and GMP certificates for translation into Spanish, prepare Spanish labelling and insert artwork for DIGEMID approval, and supply the batch-level certificates of analysis and retention-sample discipline that a Director Técnico needs in order to defend a product line. Where a buyer's route runs through the PAHO Strategic Fund rather than a national tender, we work to the quality-assurance expectations that channel applies.
Buyers stay with Farbe Firma because we are straightforward about what the Peruvian route actually involves. India is not on DIGEMID's high-sanitary-surveillance list and is not a PIC/S participating authority, so an Indian GMP certificate will not substitute for a DIGEMID BPM certificate; the plant has to be inspected, and the inspection travel costs sit with the applicant company. That regime has become markedly stricter — DIGEMID assessed 70 plants across six countries between November 2025 and May 2026, and of the first 51 inspected only 20 were certified, while product registrations tied to failed sites have been suspended. We regard that tightening as an advantage rather than an obstacle, because it removes suppliers who cannot demonstrate control, and because Peruvian buyers have good reason to insist on it. We would rather set out the timeline, the inspection obligation and the local-partner requirement honestly at the first meeting than discover the gap at the point of filing.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Peru?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Peru specifically, we supply CTD-format dossiers, apostilled Certificates of Pharmaceutical Product and GMP certificates for Spanish translation, Zone IVa and Zone IVb stability data, and Spanish labelling and insert artwork for DIGEMID approval. Because the Registro Sanitario must be held by a Peruvian pharmaceutical establishment, we work alongside a client's droguería and its Químico Farmacéutico Director Técnico rather than filing in our own name.
How does an imported injectable get registered in Peru, and how long is the registration valid?
The marketing authorisation is the Registro Sanitario, granted by DIGEMID under Ley N° 29459 and DS N° 016-2011-SA. It is valid for five years and renewable, and is filed on a CTD-structured dossier submitted electronically. The application is signed by the legal representative or the Químico Farmacéutico Director Técnico of a Peruvian droguería holding a Buenas Prácticas de Almacenamiento certificate. The dossier includes a Certificate of Pharmaceutical Product in WHO format, a GMP certificate, quality and stability documentation, and labelling artwork for approval. The statutory evaluation period is short, but applicants should plan for a materially longer real-world timeline, and should apply for renewal well ahead of expiry.
Does DIGEMID accept an Indian WHO-GMP certificate, or does it inspect the factory itself?
DIGEMID accepts a foreign GMP certificate only when it is issued by one of the twenty countries on its “países de alta vigilancia sanitaria” list, which comprises largely European, North American and East Asian regulators plus the EMA. India is not on that list, and India is not a PIC/S participating authority, so there is no mutual-recognition route. An Indian manufacturer therefore needs a BPM certificate issued by DIGEMID itself on the basis of an on-site inspection in India, with the inspection travel and per-diem costs borne by the requesting company. A transitional arrangement has allowed plants awaiting inspection to continue supplying, but DIGEMID has stated its intention to close that gap, so manufacturers should treat inspection readiness as an immediate requirement rather than a future one.
Which stability data does Peru require for sterile injectables?
Peru is classified as ICH Climatic Zone IVa. The long-term storage condition is 30°C ± 2°C at 65% ± 5% relative humidity, with accelerated testing at 40°C ± 2°C and 75% ± 5% RH, and a minimum of twelve months of real-time data. Farbe Firma as a matter of course also holds Zone IVb data at 30°C/75% RH, which is more demanding than the Peruvian requirement, covers distribution into the humid Amazon regions, and allows the same stability package to support registrations across other tropical markets without repeating the study.
Which public procurement channels matter for injectables in Peru?
There are four that matter. CENARES runs centralised and corporate purchases for the Ministry of Health and the regional governments, and has been programming purchases forward into 2026 and 2027. EsSalud procures separately for its own hospital network. Regional governments buy for regional hospitals. Tenders are published through the national electronic procurement platform, with reverse auctions and framework agreements run through Perú Compras. Inclusion on the Petitorio Nacional Único de Medicamentos Esenciales is effectively a precondition for public-sector volume. A fifth route worth noting is the PAHO Strategic Fund, a regional pooled-procurement mechanism whose quality-assurance requirements differ from the national pathway.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments